{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T13:14:14Z","timestamp":1776950054170,"version":"3.51.4"},"reference-count":98,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.clindermatol.2011.03.014","type":"journal-article","created":{"date-parts":[[2011,12,8]],"date-time":"2011-12-08T19:23:41Z","timestamp":1323372221000},"page":"84-94","source":"Crossref","is-referenced-by-count":67,"title":["Current therapy of the pemphigus group"],"prefix":"10.1016","volume":"30","author":[{"given":"Michael","family":"Kasperkiewicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enno","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Detlef","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2011.03.014_bb0005","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2174\/157016309789869065","article-title":"Current treatment of autoimmune blistering diseases","volume":"6","author":"Kasperkiewicz","year":"2009","journal-title":"Curr Drug Discov Technol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archderm.1996.03890260105016","article-title":"The adjuvant therapy of pemphigus. An update","volume":"132","author":"Bystryn","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0015","first-page":"CD006263","article-title":"Interventions for pemphigus vulgaris and pemphigus foliaceus","author":"Martin","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0020","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/archderm.1988.01670110019004","article-title":"Controlled study of plasma exchange in pemphigus","volume":"124","author":"Guillaume","year":"1988","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0025","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-4362.1990.tb04765.x","article-title":"Pemphigus therapy with oral prednisolone regimens. A 5-year study","volume":"29","author":"Ratnam","year":"1990","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0030","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1365-4362.1994.tb01003.x","article-title":"Treatment of oral pemphigus vulgaris","volume":"33","author":"Chrysomallis","year":"1994","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0035","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1001\/archderm.136.7.868","article-title":"Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus","volume":"136","author":"Ioannides","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0040","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1468-3083.2002.00461.x","article-title":"Pemphigus vulgaris with oral involvement: evaluation of two different systemic corticosteroid therapeutic protocols","volume":"16","author":"Femiano","year":"2002","journal-title":"J Eur Acad Derm Venereol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0045","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1610-0378.2005.04747.x","article-title":"Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study","volume":"3","author":"Rose","year":"2005","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0050","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1001\/archderm.142.5.570","article-title":"Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial","volume":"142","author":"Mentink","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0055","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1001\/archderm.142.11.1447","article-title":"A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus","volume":"142","author":"Beissert","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0060","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaad.2007.05.024","article-title":"Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris","volume":"57","author":"Chams-Davatchi","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0065","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1468-3083.2006.01873.x","article-title":"Accelerating effects of epidermal growth factor on skin lesions of pemphigus vulgaris: a double-blind, randomized, controlled trial","volume":"21","author":"Tabrizi","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0070","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/archderm.144.1.25","article-title":"Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris","volume":"144","author":"Werth","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0075","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2133.2009.09208.x","article-title":"The use of sulfasalazine and pentoxifylline (low-cost antitumour necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: a comparative study","volume":"161","author":"el-Darouti","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0080","doi-asserted-by":"crossref","first-page":"476","DOI":"10.4103\/0378-6323.55390","article-title":"Randomized open comparative trial of dexamethasone-cyclophosphamide pulse and daily oral cyclophosphamide versus cyclophosphamide pulse and daily oral prednisolone in pemphigus vulgaris","volume":"75","author":"Sethy","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0085","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","article-title":"A randomized double-blind trial of intravenous immunoglobulin for pemphigus","volume":"60","author":"Amagai","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0090","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2133.2009.09034.x","article-title":"An \u2018n-of-1\u2019 placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris","volume":"160","author":"Arnold","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0095","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/jid.2010.91","article-title":"Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial","volume":"130","author":"Beissert","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0100","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1529-8019.2010.01329.x","article-title":"The efficacy of nicotinamide gel 4% as an adjuvant therapy in the treatment of cutaneous erosions of pemphigus vulgaris","volume":"23","author":"Iraji","year":"2010","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0105","first-page":"684","article-title":"Pimecrolimus 1% cream in the treatment of cutaneous lesions of pemphigus vulgaris: a double-blind, placebo-controlled clinical trial","volume":"9","author":"Iraji","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0110","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1001\/archderm.1996.03890360021005","article-title":"Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids","volume":"132","author":"Werth","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0115","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1365-2133.2003.05665.x","article-title":"Guidelines for the management of pemphigus vulgaris","volume":"149","author":"Harman","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0120","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clindermatol.2009.06.018","article-title":"Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: facts and controversies","volume":"28","author":"Schiavo","year":"2010","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0125","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1468-3083.2010.03753.x","article-title":"High dose oral prednisone vs. prednisone plus azathioprine for the treatment of oral pemphigus: a retrospective, bi-centre, comparative study","volume":"25","author":"Chaidemenos","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0130","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1365-2133.2004.06323.x","article-title":"British Association of Dermatologists Therapy, Guidelines and Audit Subcommittee. Guidelines for prescribing azathioprine in dermatology","volume":"151","author":"Anstey","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0135","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/archderm.135.1.54","article-title":"Mycophenolate is effective in the treatment of pemphigus vulgaris","volume":"135","author":"Enk","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0140","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archderm.139.6.739","article-title":"Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil","volume":"139","author":"Mimouni","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0145","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1046\/j.1365-2133.2003.05269.x","article-title":"An evaluation of the usefulness of mycophenolate mofetil in pemphigus","volume":"149","author":"Powell","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0150","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jaad.2010.02.052","article-title":"Therapeutic ladder for pemphigus vulgaris: emphasis on achieving complete remission","volume":"64","author":"Strowd","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0155","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00128071-200708020-00004","article-title":"Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris","volume":"8","author":"Olszewska","year":"2007","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0160","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1067\/S0190-9622(03)00859-4","article-title":"Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus","volume":"49","author":"Cummins","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0165","first-page":"199","article-title":"Pulse therapy with dexamethasone-cyclophosphamide in pemphigus","volume":"50","author":"Pasricha","year":"1984","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0170","first-page":"1","article-title":"Pulse versus oral methylprednisolone therapy in pemphigus vulgaris","volume":"10","author":"Shahidi-Dadras","year":"2007","journal-title":"Arch Iran Med"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0175","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/08916930600972008","article-title":"Pemphigus: a treatment update","volume":"39","author":"Dick","year":"2006","journal-title":"Autoimmunity"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0180","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0190-9622(97)70296-2","article-title":"Long-term remission in selected patients with pemphigus vulgaris treated with cyclosporine","volume":"36","author":"Mobini","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0185","first-page":"505","article-title":"Cyclosporine therapy should be considered for maintenance of remission in patients with pemphigus","volume":"137","author":"Vardy","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0190","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000314155","article-title":"Recalcitrant pemphigus vulgaris responding to systemic tacrolimus","volume":"221","author":"B\u00fcsing","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0195","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1001\/archderm.135.10.1275","article-title":"Methotrexate as an adjuvant treatment for pemphigus vulgaris","volume":"135","author":"Smith","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0200","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1365-2133.2009.09246.x","article-title":"Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid","volume":"161","author":"G\u00fcrcan","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0205","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00105-006-1102-2","article-title":"Gold. Effective therapy for mucosal lesions of pemphigus vulgaris","volume":"58","author":"Lange","year":"2007","journal-title":"Hautarzt"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0210","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archderm.134.9.1104","article-title":"Treatment of pemphigus with gold","volume":"134","author":"Pandya","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0215","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0190-9622(08)80651-2","article-title":"Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases","volume":"28","author":"Chaffins","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0220","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/archderm.1995.01690230121025","article-title":"Is the combination of tetracycline and nicotinamide therapy alone effective in pemphigus?","volume":"131","author":"Alpsoy","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0225","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/11310740-000000000-00000","article-title":"Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data","volume":"10","author":"G\u00fcrcan","year":"2009","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0230","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/archderm.141.6.699","article-title":"Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris","volume":"141","author":"Heaphy","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0235","first-page":"383","article-title":"Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity","volume":"8","author":"D'Auria","year":"1997","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0240","first-page":"121","article-title":"ICAM-1, ELAM-1, TNF-alpha and IL-6 in serum and blister liquid of pemphigus vulgaris patients","volume":"58","author":"Alecu","year":"1999","journal-title":"Roum Arch Microbiol Immunol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0245","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1523-1747.2000.00835.x","article-title":"In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis","volume":"114","author":"Feliciani","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0250","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-4362.2001.01083.x","article-title":"TNFalpha and IL-6 are mediators in the blistering process of pemphigus","volume":"40","author":"L\u00f3pez-Robles","year":"2001","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0255","first-page":"339","article-title":"Cytokines in autoimmune bullous skin diseases. Epiphenomena or contribution to pathogenesis?","volume":"144","author":"Ludwig","year":"2009","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0260","first-page":"940","article-title":"Successful treatment of pemphigus vulgaris with etanercept in four patients","volume":"8","author":"Shetty","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0265","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1468-3083.2008.02929.x","article-title":"Development of pemphigus vulgaris in a patient with psoriasis treated with etanercept","volume":"23","author":"Daulat","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0270","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1159\/000243805","article-title":"Bullous pemphigoid during long-term TNF-alpha blocker therapy","volume":"219","author":"Bordignon","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0275","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1111\/j.1365-2230.2008.03204.x","article-title":"Development of bullous pemphigoid during treatment of psoriasis with adalimumab","volume":"34","author":"Stausb\u00f8l-Gr\u00f8n","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0280","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0190-9622(89)80148-3","article-title":"High-dosage intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid","volume":"20","author":"Tappeiner","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0285","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0190-9622(08)80783-9","article-title":"Effects of intravenous gamma-globulin in pemphigus","volume":"22","author":"Humbert","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0290","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s12016-009-8153-y","article-title":"High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases","volume":"38","author":"Ishii","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0295","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/11533290-000000000-00000","article-title":"Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety","volume":"11","author":"G\u00fcrcan","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0300","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.intimp.2005.11.002","article-title":"Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases","volume":"6","author":"Daoud","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0305","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1172\/JCI24394","article-title":"Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases","volume":"115","author":"Li","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0310","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0002-9440(10)61239-4","article-title":"Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in Pemphigus","volume":"167","author":"Arredondo","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0315","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","article-title":"Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation","volume":"313","author":"Kaneko","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0320","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1365-2249.2010.04265.x","article-title":"Efficacy of intravenous immunoglobulin (IVIG) affinity-purified antidesmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris","volume":"162","author":"Mimouni","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0325","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2310\/7750.2006.00048","article-title":"Canadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology","volume":"10","author":"Mydlarski","year":"2006","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0330","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1684\/ejd.2008.0580","article-title":"Guidelines on the use of high-dose intravenous immunoglobulin in dermatology","volume":"19","author":"Enk","year":"2009","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0335","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1610-0387.2009.07118.x","article-title":"Use of high-dose immunoglobulins in dermatology","volume":"7","author":"Enk","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0340","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2133.1978.tb01631.x","article-title":"Plasma exchange in the treatment of pemphigus vulgaris","volume":"98","author":"Cotterill","year":"1978","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0345","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/archderm.1983.01650270033013","article-title":"Plasma exchange in pemphigus. Uncontrolled study of ten patients","volume":"119","author":"Roujeau","year":"1983","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0350","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0190-9622(90)70004-2","article-title":"Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies","volume":"22","author":"Tan-Lim","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0355","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2340\/0001555575150152","article-title":"The steroid-sparing effect of long-term plasmapheresis in pemphigus","volume":"75","author":"S\u00f8ndergaard","year":"1995","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0360","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1067\/mjd.2000.109297","article-title":"The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris","volume":"43","author":"Turner","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0365","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1517\/13543784.9.9.2017","article-title":"Immunoadsorption, current status and future developments","volume":"9","author":"Braun","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0370","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00403-009-1024-9","article-title":"Immunoadsorption in dermatology","volume":"302","author":"Schmidt","year":"2010","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0375","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1610-0387.2007.06342.x","article-title":"Recommendations for the use of\u00a0immunoapheresis in the treatment of autoimmune bullous diseases","volume":"5","author":"Zillikens","year":"2007","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0380","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1046\/j.1365-2133.2003.05302.x","article-title":"Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus","volume":"148","author":"Schmidt","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0385","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2230.2006.02220.x","article-title":"Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption","volume":"31","author":"Shimanovich","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0390","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12016-007-8021-6","article-title":"Rituximab in treatment-resistant autoimmune blistering skin disorders","volume":"34","author":"Schmidt","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0395","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1749-6632.2009.04744.x","article-title":"Rituximab in severe pemphigus","volume":"1173","author":"Schmidt","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0400","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1038\/jid.2008.330","article-title":"Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion","volume":"128","author":"Zambruno","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0405","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1038\/jid.2008.172","article-title":"Rituximab exerts a dual effect in pemphigus vulgaris","volume":"128","author":"Eming","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0410","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2230.2006.02151.x","article-title":"Rituximab in refractory autoimmune bullous diseases","volume":"31","author":"Schmidt","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0415","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0420","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0425","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.intimp.2004.04.015","article-title":"Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG","volume":"4","author":"Vugmeyster","year":"2004","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0430","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0435","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0440","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/jid.2008.178","article-title":"B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses","volume":"128","author":"Mouquet","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0445","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrd2085","article-title":"B cells move to centre stage: novel opportunities for autoimmune disease treatment","volume":"5","author":"Browning","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0450","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2002-06-1639","article-title":"Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance","volume":"101","author":"Manshouri","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0455","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.clim.2009.05.007","article-title":"Immunogenicity of rituximab in patients with severe pemphigus","volume":"132","author":"Schmidt","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0460","article-title":"Rituximab for treatment-refractory pemphigus and pemphigoid: A case series of 17 patients","author":"Kasperkiewicz","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0465","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1365-2133.2007.08358.x","article-title":"Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins","volume":"158","author":"Shimanovich","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0470","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","article-title":"Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases","volume":"6","author":"Hertl","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0475","first-page":"S97","article-title":"Successful treatment of severe pemphigus with the combination of immunoadsorption and rituximab","volume":"129","author":"Shimanovich","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0480","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2230.1995.tb01327.x","article-title":"Management of the immunobullous disorders. II. Pemphigus","volume":"20","author":"Huilgol","year":"1995","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0485","first-page":"142","article-title":"Topical tacrolimus: a novel therapeutic intervention for recalcitrant labial pemphigus vulgaris","volume":"13","author":"Hodgson","year":"2003","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.014_bb0490","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/0190-9622(90)70352-I","article-title":"Topical cyclosporine for oral mucosal disorders","volume":"23","author":"Eisen","year":"1990","journal-title":"J Am Acad Dermatol"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X11000903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X11000903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T16:06:22Z","timestamp":1713197182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X11000903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0738081X11000903"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2011.03.014","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}